Back to search

Article

Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination

2022-01-29

Abstract excerpt

<h4>Background</h4> The use of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac) against SARS-CoV-2 is implemented worldwide. However, waning immunity and breakthrough infections have been observed. Therefore, we hypothesized that the heterologous booster might improve the protection against the delta and omicron variants. <h4>Methods</h4> A total of 224 individuals wh...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
65c624eb-0d94-5208-a508-769834439203
DOI
10.1101/2022.01.28.22269986
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac VaccinationDOI 10.1101/2022.01.28.22269986
Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac VaccinationSemantic proximity
The Efficacy for the Booster Dose of Covid-19 Vaccine between Sars-Cov-2 Omicron Variant and a Two-Year Longitudinal Antibody on Wild Type ConvalescentsSemantic proximity
Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron VariantSemantic proximity
Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 StudySemantic proximity
Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boostSemantic proximity
Effects of boosted mRNA and adenoviral‐vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccinationSemantic proximity
Titers and capacity of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: a single-blinded, randomized clinical trialSemantic proximity
Antibody Response of Heterologous vs Homologous mRNA Vaccine Boosters Against the SARS-CoV-2 Omicron Variant: Interim Results from the PRIBIVAC Study, A Randomized Clinical TrialSemantic proximity
Immunogenicity and Safety of COVID-19 Booster Vaccination: A Real-World Clinical Trial to Identify the Best Vaccination StratagySemantic proximity
A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two dosesSemantic proximity
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variantSemantic proximity
Immunogenicity and clinical outcomes of booster mRNA vaccine BNT162b2 in primary antibody deficienciesSemantic proximity
Select a neighboring publication to make it the new centre.